Insulin, Neurogenetics and Memory in Alzheimer's Disease

This study has been completed.
Information provided by:
VA Office of Research and Development Identifier:
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Condition Intervention Phase
Alzheimer Disease
Drug: rosiglitazone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Study Start Date: October 1999
Estimated Study Completion Date: March 2003

Ages Eligible for Study:   55 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018382

United States, Washington
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Sponsors and Collaborators
VA Office of Research and Development
Investigator: Steven Kahn, M.D.
Investigator: Sanjay Asthana, M.D.
Investigator: Alfred Fujimoto, M.D.
  More Information

No publications provided Identifier: NCT00018382     History of Changes
Other Study ID Numbers: AGCG-012-98S
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 27, 2015